Executive Group Director Physician – Cardiovascular Diseases, Early Clinical Development CVRM

Are you an experienced cardiologist with clinical expertise in the management of patients with atherosclerosis, dyslipidemia, and heart failure? Do you have well-developed clinical research skills and knowledge? Join us to be part of a versatile and high peforming team of clinical research professionals, clinical scientists, and physicians who are translating scientific discoveries into early phase clinical development plans and clinical studies across a wide range of chronic and debilitating diseases!

At AstraZeneca, we’re dedicated to being a Great Place to Work with a inclusive and diverse team of hard-working colleagues who work in a trusting, and collaborative work environment.  We are committed to improving the health care and quality of life for patients across a wide range of diseases and disorders by developing innovative therapies that address unment clinical needs and that provide clinicians with novel evidence-based treatment options that enable them to optimize the care of their patients.

Who We Are

In the Cardiovascular, Renal, and Metabolism (CVRM) Early Clinical Development team, we are investigating the drivers of CVRM disease progression through ground breaking scientific methods and data-driven drug discovery approaches. In this context, we are investigating a wide range of different drug modalities from our rich Early CVRM portfolio of componds across diverse populations with cardiovascular and cardio-metabolic diseases.

Early Clinical Development (ECD), part of the Early CVRM Department, is where science meets clinical drug development with a focus upon delivering innovative, early phase clinical studies and accelerating human target validation while collaborating closely with our late phase clinical development and regulatory colleagues who guide our pivotal phase 3 clinical studies. We are a diverse team of experienced physicians, clinical scientists, and clinical program directors who collaborate to delineate early phase clinical development strategies, design innovative phase I-IIb clinical trials, develop and validate novel surrogate endpoints, and translate novel scientific ideas to proof of concept studies in targeted patient populations.

We are recruiting an Executive Group Director, Team Leader for the Cardiovascular Disease Physicians group, to lead our work in Atherosclerosis, Dyslipidemia, and Heart Failure. In this role, you will have the opportunity to work at the forefront of early clinical and translational research within CVRM. In a multidisciplinary environment, you will play a key role in progressing a rich and diverse pipeline of both small and large molecules in numerous active clinical programs. Additionally, you will be a member of the ECD and Early CVRM leadership teams. The role can be located at any of AstraZeneca’s vibrant R&D sites in Gaithersburg, Maryland US, Cambridge UK or Gothenburg Sweden.

What you’ll do

You will be responsible for overseeing our early phase I-IIb global clinical trials and related clinical research projects for compounds that are targeting atherosclerotic cardiovascular disease, dyslipidemia, and heart failure, as well as serving as an expert on the design, conduct, monitoring, data interpretation, and reporting of these studies. In this role, you will work on cross-functional teams within our ECD group and across the broader Early CVRM department that are framing our strategies and development plans for compounds that are targeting major metabolic disorders, such as Diabetes Mellitus, Obesity, and NASH, given that these disorders intersect with cardiovascular disease, dyslipidemia, and heart failure and influence disease progression. Furthermore, you’ll lead and mentor a team of cardiovascular disease physicians across our R & D sites to ensure that our scientific and clinical development strategies are implemented. We will rely on you to:

• Oversee all aspects of the design and operational implementation of early-stage clinical projects in the cardiovascular disease, dyslipidemia, and heart failure portfolio of Early CVRM.  You wil also ensure that all clinical programs under your purview are scientifically thorough, are clinically sound and valid, are operationally successful, and adhere to Good Clinical Practice and regulatory requirements
• Oversee, mentor, inspire, and manage a team of cardiovascular disease physicians across our R & D sites who will design scientifically thorough, innovative, and efficient early phase clinical study protocols that are aligned with the pre-clinical scientific findings and clinical development plans for each compound, while ensuring seamless transition of early clinical programs to late stage development clinical